#cvCAD
Dr. Fred Kusumoto reflects on evolving science across #cvCAD & structural heart disease from #TCT2026 & looks ahead to the latest advances in #cvPrev at #ScientificSessions26.

🔬 Catch up on the science shaping CV care w/ ACC’s Meeting Coverage ➡️ https://bit.ly/4iuTCy6 #CardioSky
November 5, 2026 at 7:30 PM
#TCT2026 IRIS-MAIN: No statistically significant difference in long-term all-cause mortality was observed among Asian patients with unprotected left main coronary artery disease who underwent #PCI or #CABG.

🔗 https://bit.ly/4zsuPC7 #cvCAD #CardioSky
November 3, 2026 at 8:30 PM
🧬 Today is #FHAwarenessDay!

FH is a genetic condition that affects millions of people. 🌍 Early detection is especially important because when left untreated individuals have a 20-fold increase in early #cvCAD.

Learn more with #ACCEd ➡️ https://bit.ly/46eZVAe

#KnowFH #CardioSky
September 24, 2026 at 1:30 PM
Late-breaking science at #ESCCongress: AIR-STEMI, PRESCISE-MI and TARGET CTA tackle some of cardiology's biggest questions. AIR-STEMI found functionally guided complete revascularization improved outcomes in #STEMI with multivessel #cvCAD.

Read more: bit.ly/46uDEOG

#CardioSky #Cardiology
August 30, 2026 at 8:19 AM
PRO-TAVI: Older patients w/ #cvCAD for whom #PCI was deferred until after TAVI had similar outcomes as those for whom it was not deferred.

Learn more about this & other #ACC26 Structural Intervention Trials, including PROTECT H2H & SURViV. ➡️ https://bit.ly/4cv5iPH #ACCIC #CardioSky
April 27, 2026 at 6:52 PM
Older patients with #cvCAD for whom #PCI was deferred until after TAVI had similar outcomes as those for whom it was not deferred, according to findings from the PRO-TAVI study presented in a Late-Breaking Clinical Trial session at #ACC26.

Learn more: https://bit.ly/4sFz75F
March 29, 2026 at 9:25 PM
🚨 Key Findings From #ACC26 ALL-RISE

FFRangio, a minimally invasive, AI-assisted, novel method of measuring fractional flow reserve (FFR), performed similarly to traditional wire-based testing in patients with #cvCAD undergoing assessment for #PCI.

More: https://bit.ly/4s3mGPZ #CardioSky
March 29, 2026 at 2:45 PM
Stress CMR-guided #cvImaging in patients w/ chest pain & nonobstructive #cvCAD was superior to angiography only in correctly diagnosing microvascular angina & improving chest pain symptoms & QoL, based on findings from CorCMR trial presented at #AHA25. 🔗 https://bit.ly/4hRZ0dJ
November 10, 2025 at 3:30 PM
Four key plasma proteins associated w/ potential causal roles in blood pressure regulation and increased risk of cardiovascular events, including #cvCAD and stroke, were identified in a Mendelian randomization study.

Read the journal scan for more ➡️ https://bit.ly/435QUZ3
Key Plasma Proteins Linked to Causal Roles in BP Regulation and Risk of CV Events - American College of Cardiology
bit.ly
October 29, 2025 at 8:00 PM
🏆 Congratulations to the #ACCMidEast abstract competition winners! Their research explores:
📊 Non-HDL-C levels in Middle Eastern #ASCVD patients
🫀 LVMI impact on RV impairment
🔬Comparative efficacy of imaging agents in detecting #cvCAD

🔗 https://bit.ly/3WnSt0v

#ACCIntl
October 8, 2025 at 3:19 PM
Noninferiority was not demonstrated in the OPTION-STEMI trial comparing immediate complete revascularization with staged complete revascularization in patients with #STEMI and multivessel CAD. Read more: https://bit.ly/47QKKyX

#ESCCongress #cvCAD
August 31, 2025 at 3:55 PM
As compared with SPECT myocardial perfusion imaging, vasodilator stress #CMR has superior specificity and accuracy for detection of obstructive #cvCAD. Sensitivity of the two modalities is not significantly different. #medblue #meded
November 11, 2023 at 8:31 PM
GPS-CAD is the largest global study of race, ethnicity, and environment in ACAD, spanning 6 continents. It is the first to examine how country and race/ethnicity shape atherosclerosis vs traditional risk factors to inform local strategies. https://bit.ly/4uT0aMp #JACCAsia #ACC26 #cvCAD #CardioSky
March 28, 2026 at 6:40 PM
In patients with de novo coronary artery disease, #DCB angioplasty with rescue stenting was associated with a higher rate of Device-oriented Composite Endpoint compared to intended DES implantation regarding DoCE at 3 years. https://bit.ly/4nePRNp

#TCT2025 #JACC #cvCAD #CardioSky
October 27, 2025 at 10:00 PM
FFR-guided #PCI using zotarolimus DES provides significantly better long-term value than CABG for treatment of patients with multivessel CAD, with equivalent clinical outcomes at substantially lower cost. https://bit.ly/47vJgJS

#TCT2025 #JACC #cvCABG #cvCAD #CardioSky
October 25, 2025 at 3:20 PM